American Heart Association (AHA) Scientific Sessions 2023

Philadelphia, Pennsylvania, US 11 November 2023 - 13 November 2023

Add-on PCSK9 inhibitor cuts LDL-C by half, allows infrequent dosing in patients maxed out on statins

19 Dec 2023 by

Injection with the novel, long-acting PCSK9 inhibitor recaticimab once every 3 months reduces LDL-cholesterol (LDL-C) levels by >50 percent compared with placebo in patients already maxed out on statins in the phase III REMAIN-2 trial.

Add-on PCSK9 inhibitor cuts LDL-C by half, allows infrequent dosing in patients maxed out on statins

19 Dec 2023

AI-guided stethoscope helps detect cardiomyopathy during pregnancy

18 Dec 2023 by

A screening programme that incorporates artificial intelligence (AI)-guided digital stethoscope improves clinicians’ ability to detect peripartum cardiomyopathy in the Nigerian SPEC-AI trial.

AI-guided stethoscope helps detect cardiomyopathy during pregnancy

18 Dec 2023

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

05 Dec 2023 by

In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.

Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients

05 Dec 2023

Some signal of benefit found for liberal transfusion strategy for anaemic heart attack patients

28 Nov 2023 by

Adopting a liberal blood transfusion strategy in patients with acute myocardial infarction (AMI) and anaemia does not appear to do much in terms of reducing the risk of AMI recurrence or death compared with a restrictive transfusion strategy, although there appears to be a hint of benefit, as shown in the results of the phase III MINT trial.

Some signal of benefit found for liberal transfusion strategy for anaemic heart attack patients

28 Nov 2023

Self-monitoring improves postpartum BP control in women with hypertensive pregnancy

27 Nov 2023 by

Empowering mums to self-monitor their blood pressure (BP) with a physician-guided titration of antihypertensive medications helps lower postpartum BP level after a pregnancy complicated by hypertension, as shown in the POP-HT trial.

Self-monitoring improves postpartum BP control in women with hypertensive pregnancy

27 Nov 2023

Intensive BP-lowering reduces dementia risk in patients with hypertension

23 Nov 2023 by

Among Chinese patients with hypertension, a 48-month intensive blood pressure (BP) intervention programme significantly reduces the risk of developing dementia than usual care, according to a study presented at AHA 2023.

Intensive BP-lowering reduces dementia risk in patients with hypertension

23 Nov 2023

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023 by

Treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) among overweight/obese patients with pre-existing cardiovascular (CV) disease but without type 2 diabetes (T2D), according to the SELECT trial presented at AHA 2023.

Semaglutide reduces CV risk in overweight/obese patients without T2D

21 Nov 2023

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023 by

Use of antihypertensive medications does not appear to reduce the risk of all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF), reports a study presented at AHA 2023. However, treatment with antihypertensives can lower the risk of adverse cardiovascular (CV) outcomes regardless of the patient’s hypertension status.

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023 by

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023

Low-sodium diet delivers rapid BP-lowering effect

16 Nov 2023 by

In the CARDIA-SSBP study, low sodium intake led to a rapid reduction in blood pressure (BP) in middle-aged individuals.

Low-sodium diet delivers rapid BP-lowering effect

16 Nov 2023